N-Acetylglucosamine: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Added a new source about the newest medical research
Tags: Visual edit Mobile edit Mobile web edit
Line 149: Line 149:


==Medical uses==
==Medical uses==
It has been proposed as a treatment for [[autoimmune]] diseases and recent tests have claimed some success.<ref name="pmid21965673">{{cite journal | vauthors=Grigorian A, Araujo L, Naidu NN, Place DJ, Choudhury B, Demetriou M | title=N-Acetylglucosamine Inhibits T-helper 1 (Th1)/T-helper 17 (Th17) Cell Responses and Treats Experimental Autoimmune Encephalomyelitis | journal=[[Journal of Biological Chemistry]] | volume=286 | pages=40133–40141 | year=2011 | issue=46 | doi=10.1074/jbc.M111.277814 | pmc=3220534| pmid=21965673}}</ref>
It has been proposed as a treatment for [[autoimmune]] diseases and recent tests have claimed some success.<ref name="pmid21965673">{{cite journal | vauthors=Grigorian A, Araujo L, Naidu NN, Place DJ, Choudhury B, Demetriou M | title=N-Acetylglucosamine Inhibits T-helper 1 (Th1)/T-helper 17 (Th17) Cell Responses and Treats Experimental Autoimmune Encephalomyelitis | journal=[[Journal of Biological Chemistry]] | volume=286 | pages=40133–40141 | year=2011 | issue=46 | doi=10.1074/jbc.M111.277814 | pmc=3220534| pmid=21965673}}</ref><ref>{{Cite journal |last=Sy |first=Michael |last2=Newton |first2=Barbara L. |last3=Pawling |first3=Judy |last4=Hayama |first4=Ken L. |last5=Cordon |first5=Andres |last6=Yu |first6=Zhaoxia |last7=Kuhle |first7=Jens |last8=Dennis |first8=James W. |last9=Brandt |first9=Alexander U. |last10=Demetriou |first10=Michael |date=2023-09-13 |title=N-acetylglucosamine inhibits inflammation and neurodegeneration markers in multiple sclerosis: a mechanistic trial |url=https://doi.org/10.1186/s12974-023-02893-9 |journal=Journal of Neuroinflammation |volume=20 |issue=1 |pages=209 |doi=10.1186/s12974-023-02893-9 |issn=1742-2094 |pmc=PMC10498575 |pmid=37705084}}</ref>


==''O''-GlcNAcylation==
==''O''-GlcNAcylation==

Revision as of 21:03, 6 October 2023

"GlcNAc" redirects here. Not to be confused with GlyNAC.
N-Acetylglucosamine

Names
IUPAC name
β-D-(Acetylamino)-2-deoxy-glucopyranose
Other names
N-Acetyl-D-glucosamine
GlcNAc
NAG
Identifiers
3D model (JSmol)
1247660
ChEBI
ChEMBL
ChemSpider
ECHA InfoCard 100.028.517 Edit this at Wikidata
EC Number
  • 231-368-2
721281
KEGG
UNII
  • InChI=1S/C8H15NO6/c1-3(11)9-5-7(13)6(12)4(2-10)15-8(5)14/h4-8,10,12-14H,2H2,1H3,(H,9,11)/t4-,5-,6-,7-,8-/m1/s1 checkY
    Key: OVRNDRQMDRJTHS-FMDGEEDCSA-N checkY
  • InChI=1/C8H15NO6/c1-3(11)9-5-7(13)6(12)4(2-10)15-8(5)14/h4-8,10,12-14H,2H2,1H3,(H,9,11)/t4-,5-,6-,7-,8-/m1/s1
    Key: OVRNDRQMDRJTHS-FMDGEEDCBL
  • O=C(N[C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@H]1O)CO)C
Properties
C8H15NO6
Molar mass 221.21
Melting point 211
Related compounds
Related Monosaccharides
 N-Acetylgalactosamine
Related compounds
 Glucosamine
Glucose
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)
N-Acetylglucosamine molecule

N-Acetylglucosamine (GlcNAc) is an amide derivative of the monosaccharide glucose. It is a secondary amide between glucosamine and acetic acid. It is significant in several biological systems.

It is part of a biopolymer in the bacterial cell wall, which is built from alternating units of GlcNAc and N-acetylmuramic acid (MurNAc), cross-linked with oligopeptides at the lactic acid residue of MurNAc. This layered structure is called peptidoglycan (formerly called murein).

GlcNAc is the monomeric unit of the polymer chitin, which forms the exoskeletons of arthropods like insects and crustaceans. It is the main component of the radulas of mollusks, the beaks of cephalopods, and a major component of the cell walls of most fungi.

Polymerized with glucuronic acid, it forms hyaluronan.

GlcNAc has been reported to be an inhibitor of elastase release from human polymorphonuclear leukocytes (range 8–17% inhibition), however this is much weaker than the inhibition seen with N-acetylgalactosamine (range 92–100%).[1]

Medical uses

It has been proposed as a treatment for autoimmune diseases and recent tests have claimed some success.[2][3]

O-GlcNAcylation

Main article: O-GlcNAc

O-GlcNAcylation is the process of adding a single N-acetylglucosamine sugar to the serine or threonine of a protein.[4] Comparable to phosphorylation, addition or removal of N-acetylglucosamine is a means of activating or deactivating enzymes or transcription factors.[4] In fact, O-GlcNAcylation and phosphorylation often compete for the same serine/threonine sites.[4] O-GlcNAcylation most often occurs on chromatin proteins, and is often seen as a response to stress.[4]

Hyperglycemia increases O-GlcNAcylation, leading to insulin resistance.[5] Increased O-GlcNAcylation due to hyperglycemia is evidently a dysfunctional form of O-GlcNAcylation. O-GlcNAcylation decline in the brain with age is associated with cognitive decline. When O-GlcNAcylation was increased in the hippocampus of aged mice, spatial learning and memory improved.[6]

See also

References

  1. ^ Kamel, M.; Hanafi, M.; Bassiouni, M. (1991). "Inhibition of elastase enzyme release from human polymorphonuclear leukocytes by N-acetyl-galactosamine and N-acetyl-glucosamine". Clinical and Experimental Rheumatology. 9 (1): 17–21. PMID 2054963.
  2. ^ Grigorian A, Araujo L, Naidu NN, Place DJ, Choudhury B, Demetriou M (2011). "N-Acetylglucosamine Inhibits T-helper 1 (Th1)/T-helper 17 (Th17) Cell Responses and Treats Experimental Autoimmune Encephalomyelitis". Journal of Biological Chemistry. 286 (46): 40133–40141. doi:10.1074/jbc.M111.277814. PMC 3220534. PMID 21965673.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  3. ^ Sy, Michael; Newton, Barbara L.; Pawling, Judy; Hayama, Ken L.; Cordon, Andres; Yu, Zhaoxia; Kuhle, Jens; Dennis, James W.; Brandt, Alexander U.; Demetriou, Michael (13 September 2023). "N-acetylglucosamine inhibits inflammation and neurodegeneration markers in multiple sclerosis: a mechanistic trial". Journal of Neuroinflammation. 20 (1): 209. doi:10.1186/s12974-023-02893-9. ISSN 1742-2094. PMC 10498575. PMID 37705084.{{cite journal}}: CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link)
  4. ^ a b c d Hart GW, Slawson C, Ramirez-Correa G, Lagerlof O (2011). "Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease". Annual Review of Biochemistry. 80: 825–858. doi:10.1146/annurev-biochem-060608-102511. PMC 3294376. PMID 21391816.
  5. ^ Ma J, Hart GW (2013). "Protein O-GlcNAcylation in diabetes and diabetic complications". Expert Review of Proteomics. 10 (4): 365–380. doi:10.1586/14789450.2013.820536. PMC 3985334. PMID 23992419.
  6. ^ Wheatley EG, Albarran E, White CW 3rd, Bieri G, Sanchez-Diaz C, Pratt K, Snethlage CE, Ding JB, Villeda SA (2019). "Neuronal O-GlcNAcylation Improves Cognitive Function in the Aged Mouse Brain". Current Biology. 29 (20): 3359–3369. doi:10.1016/j.cub.2019.08.003. PMC 7199460. PMID 31588002.

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=N-Acetylglucosamine&oldid=1178944246"